When.com Web Search

  1. Ads

    related to: cms payer price transparency report

Search results

  1. Results From The WOW.Com Content Network
  2. Physician Payments Sunshine Act - Wikipedia

    en.wikipedia.org/wiki/Physician_Payments...

    The Sunshine Act requires manufacturers of drugs, medical devices, biological and medical supplies covered by the three federal health care programs Medicare, Medicaid, and State Children's Health Insurance Program (SCHIP) to collect and track all financial relationships with physicians and teaching hospitals and to report these data to the Centers for Medicare and Medicaid Services (CMS).

  3. Opinion - Don’t blame insurers for what doctor and hospital ...

    www.aol.com/news/opinion-don-t-blame-insurers...

    From 2000 to 2020, major health systems made 1,164 mergers, only 13 of which have been challenged by the Federal Trade Commission, despite raising prices for patients, insurers and employers.

  4. Elijah Cummings Lower Drug Costs Now Act - Wikipedia

    en.wikipedia.org/wiki/Elijah_Cummings_Lower_Drug...

    Drug companies would be required to report certain pieces of information on drugs that cost more than $100 and covered by Medicare or Medicaid based on the rate of price and spending increases, or face civil penalties. One provision of which would require that drug companies report certain drug price increases at least 30 days before the price ...

  5. Health care prices in the United States - Wikipedia

    en.wikipedia.org/wiki/Health_care_prices_in_the...

    Unadjusted for timing shifts, in 2017 Medicare spending was $595 billion and Medicaid spending was $375 billion. [31] Medicare covered 57 million people as of September 2016. [32] While on the other hand, Medicaid covered 68.4 million people as of July 2017, 74.3 million including the Children's Health Insurance Program (CHIP). [33]

  6. Prescription drug prices in the United States - Wikipedia

    en.wikipedia.org/wiki/Prescription_drug_prices...

    The price of a new drug (in most cases) is limited so that the cost of therapy with the new drug is in the range of the costs of therapy with existing drugs in the same therapeutic class. The price of a breakthrough drug is limited to the median of its prices in France, Germany, Italy, Sweden, Switzerland, Britain, and the United States.

  7. 340B Drug Pricing Program - Wikipedia

    en.wikipedia.org/wiki/340B_Drug_Pricing_Program

    The report calls for a number of reforms to modernize the program, including more pricing transparency to ensure that health care providers are not being overcharged, audits of drug manufacturers, as well as a look at the use of contract pharmacies to determine whether the program is helping vulnerable patients better access prescription ...

  1. Ads

    related to: cms payer price transparency report